Bristol Myers Squibb/bms.com
May 10, 2025, 17:01
FDA approved Bristol Myers Squibb’s Opdivo + Yervoy for first-line treatment of MSI-H/dMMR metastatic colorectal cancer
Fight Colorectal Cancer shared a post on LinkedIn:
“Congratulations to Bristol Myers Squibb on the FDA approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for first-line treatment of patients with MSI-H/dMMR metastatic Colorectal Cancer!
This milestone marks a major advancement in immunotherapy for colorectal cancer, offering a powerful option for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors-an important subset of the CRC population.
At Fight CRC, we believe every colorectal cancer patient deserves access to comprehensive biomarker testing from the moment of diagnosis. Approvals like this one reinforce the value of identifying MSI-H/dMMR status early so patients can benefit from treatments that are matched to their tumor biology.”
Read more about Opdivo + Yervoy here.
Learn more about FDA and colorectal cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32